S
Snezana Agatonovic-Kustrin
Researcher at I.M. Sechenov First Moscow State Medical University
Publications - 125
Citations - 3642
Snezana Agatonovic-Kustrin is an academic researcher from I.M. Sechenov First Moscow State Medical University. The author has contributed to research in topics: Molecular descriptor & DPPH. The author has an hindex of 28, co-authored 118 publications receiving 2857 citations. Previous affiliations of Snezana Agatonovic-Kustrin include Universiti Teknologi MARA & Monash University Malaysia Campus.
Papers
More filters
Journal ArticleDOI
Cosmeceuticals Derived from Bioactive Substances Found in Marine Algae
TL;DR: The biological activities of terpenoids, carotenoids, tocopherol, phenolic compounds, polysaccharides, unsaturated fatty acids and mycosporin-like amino acids are reported in order to evaluate their potential use in future cosmetic skin care products.
Journal ArticleDOI
Ranitidine hydrochloride X-ray assay using a neural network
TL;DR: A simple X-ray powder diffractometric method with artificial neural networks for data modelling was developed to recognize and quantify two crystal modifications of ranitidine HCl in mixtures and thus, provide information about the solid state of the bulk drug.
Journal ArticleDOI
High-Performance Thin-Layer Chromatography Hyphenated with Microchemical and Biochemical Derivatizations in Bioactivity Profiling of Marine Species
TL;DR: The results suggest that these marine species have a significant number of bioactive compounds that warrant further investigation.
Journal ArticleDOI
Use of ANN modelling in structure--retention relationships of diuretics in RP-HPLC.
TL;DR: This study has demonstrated that the use ANNs techniques can result in much more efficient use of experimental information and could be the method of choice in some advanced research settings and serves as an indication of the broad potential of neural networks in chromatography analysis.
Journal ArticleDOI
Models for skin and brain penetration of major components from essential oils used in aromatherapy for dementia patients.
Snezana Agatonovic-Kustrin,Snezana Agatonovic-Kustrin,Chloe Ke Yi Chan,Vladimir Gegechkori,David W. Morton,David W. Morton +5 more
TL;DR: This work shows that a major disadvantage of novel multitarget compounds developed for the treatment of Alzheimer’s disease is the size of molecules, which cause problems in their delivery to the brain, therefore, there is a need for smaller compounds, which possess more desirable physicochemical properties and pharmacokinetics, in addition to targeted biological effects.